Ligand Set For Partnership Opportunities After Completing On Pfenex
Sets Out Strategy And Revenue Drivers After Finalizing $500m Deal
Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.
You may also be interested in...
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Pfenex has less than two months for an “A” designation for therapeutic equivalence for to be granted for its Bonsity (teriparatide) 505(b)(2) product by the US FDA if it wishes to realize maximum value under the companies’ partnership agreement with Alvogen.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.